{ "instance": { "cpix-20191231.htm": { "axisCustom": 3, "axisStandard": 28, "contextCount": 246, "dts": { "calculationLink": { "local": [ "cpix-20191231_cal.xml" ] }, "definitionLink": { "local": [ "cpix-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "cpix-20191231.htm" ] }, "labelLink": { "local": [ "cpix-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cpix-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-ref-2018-01-31.xml" ] }, "schema": { "local": [ "cpix-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 651, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 19, "http://www.cumberlandpharma.com/20191231": 3, "http://xbrl.sec.gov/dei/2019-01-31": 16, "total": 38 }, "keyCustom": 68, "keyStandard": 394, "memberCustom": 48, "memberStandard": 33, "nsprefix": "cpix", "nsuri": "http://www.cumberlandpharma.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.cumberlandpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae", "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ", "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Revenues", "role": "http://www.cumberlandpharma.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Inventories", "role": "http://www.cumberlandpharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Property and Equipment", "role": "http://www.cumberlandpharma.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Intangible Assets", "role": "http://www.cumberlandpharma.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Other Current and Other Long-term Liabilities", "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities", "shortName": "Other Current and Other Long-term Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - Debt", "role": "http://www.cumberlandpharma.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135110 - Disclosure - Shareholders' Equity", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139111 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143112 - Disclosure - Income Taxes", "role": "http://www.cumberlandpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets", "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150113 - Disclosure - Stock-Based Compensation Plans", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans", "shortName": "Stock-Based Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157114 - Disclosure - Employee Benefit Plans", "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159115 - Disclosure - Leases", "role": "http://www.cumberlandpharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165116 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2168117 - Disclosure - Market Concentrations", "role": "http://www.cumberlandpharma.com/role/MarketConcentrations", "shortName": "Market Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2171118 - Disclosure - Manufacturing and Supply Agreements", "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements", "shortName": "Manufacturing and Supply Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:EmploymentAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2173119 - Disclosure - Employment Agreements", "role": "http://www.cumberlandpharma.com/role/EmploymentAgreements", "shortName": "Employment Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:EmploymentAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2174120 - Disclosure - Discontinued Operations and Disposal Groups", "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroups", "shortName": "Discontinued Operations and Disposal Groups", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176121 - Disclosure - Commitments and Contingencies", "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2177122 - Disclosure - Quarterly Financial Information (Unaudited)", "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited", "shortName": "Quarterly Financial Information (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae (Tables)", "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables", "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Revenues (Tables)", "role": "http://www.cumberlandpharma.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Inventories (Tables)", "role": "http://www.cumberlandpharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - Property and Equipment (Tables)", "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326306 - Disclosure - Intangible Assets (Tables)", "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Other Current and Other Long-term Liabilities (Tables)", "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables", "shortName": "Other Current and Other Long-term Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344309 - Disclosure - Income Taxes (Tables)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements of Income and Comprehensive Income (Loss)", "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Income and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351310 - Disclosure - Stock-Based Compensation Plans (Tables)", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables", "shortName": "Stock-Based Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2360311 - Disclosure - Leases (Tables)", "role": "http://www.cumberlandpharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2366312 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2369313 - Disclosure - Market Concentrations (Tables)", "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsTables", "shortName": "Market Concentrations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2378314 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)", "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables", "shortName": "Quarterly Financial Information (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i3c8d771301204793a9c77dac6753bd75_D20190401-20190430", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "shortName": "Organization (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i61cef29eb1234e2fb2951d6ce01b3fdb_I20191231", "decimals": "2", "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Significant Accounting Policies (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails", "shortName": "Significant Accounting Policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ie12c2564530444a1b5c0e2b92c8162dd_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)", "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails", "shortName": "Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ie12c2564530444a1b5c0e2b92c8162dd_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "cpix:PaymentsForAssetAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Narrative (Details)", "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "-5", "first": true, "lang": null, "name": "cpix:PaymentsForAssetAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Narrative (Details)", "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i12ffe3b64bee4f60bf5c0cc3156f2f23_D20181101-20181130", "decimals": "2", "lang": null, "name": "cpix:TieredRoyaltyPaymentsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)", "role": "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails", "shortName": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i0298dd9fdc4f4d829502f86fed3db56d_D20190101-20191231", "decimals": "0", "lang": null, "name": "cpix:PaymentsForContingentConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)", "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails", "shortName": "Revenues (Schedule of Net Product Revenues by Product) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ib40376317bc64035a2da0b84d9123d5c_D20190101-20191231", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Revenues (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "shortName": "Revenues (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "-5", "lang": null, "name": "cpix:RevenueRecognitionUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Inventories (Schedule of Inventories) (Details)", "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails", "shortName": "Inventories (Schedule of Inventories) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Inventories (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "shortName": "Inventories (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)", "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Property and Equipment (Depreciation Expense) (Details)", "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails", "shortName": "Property and Equipment (Depreciation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427413 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)", "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Intangible Assets (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ifbda602c42d14511bb8c01b312e712c3_I20191231", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428414 - Disclosure - Intangible Assets (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i18ccb623bcfe4913b04e386ac56667cc_D20190101-20191231", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429415 - Disclosure - Intangible Assets Future Amortization Expense (Details)", "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails", "shortName": "Intangible Assets Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i242905b09ba14928898c52b50ce64ecf_I20161231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements of Equity", "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "shortName": "Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i242905b09ba14928898c52b50ce64ecf_I20161231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "cpix:ProductSalesRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432416 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)", "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails", "shortName": "Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "cpix:ProductSalesRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermLineOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Debt (Line of Credit) (Details)", "role": "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails", "shortName": "Debt (Line of Credit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia49def03161543f0982fbfe239a977f9_I20181017", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436418 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails", "shortName": "Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i242ae59f7075481aa58828dcd984f8f2_I20061231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - Shareholders' Equity (Warrants, Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails", "shortName": "Shareholders' Equity (Warrants, Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i242ae59f7075481aa58828dcd984f8f2_I20061231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails", "shortName": "Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "-5", "lang": null, "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i70c299b338834dbfa0bca910c3806c92_D20191001-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails", "shortName": "Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails", "shortName": "Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ic94c993c3c8d41d59c765a6f62b40d48_I20170101", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445423 - Disclosure - Income Taxes (Operating Loss Carryforwards, Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "shortName": "Income Taxes (Operating Loss Carryforwards, Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ic94c993c3c8d41d59c765a6f62b40d48_I20170101", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails", "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i88a6996277ce438694b7fbd9a4cac9eb_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447425 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails", "shortName": "Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i4fe5bf45eee34cf6a782cbfad9e11175_I20191231", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1106123 - Statement - Valuation and Qualifying Accounts", "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts", "shortName": "Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448426 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails", "shortName": "Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449427 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452428 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "shortName": "Stock-Based Compensation Plans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453429 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ida64c2b6ec064ffd9ad6682a2c4a2357_D20190101-20191231", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i680674f30ec44fb19f14337447e1df00_I20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454430 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails", "shortName": "Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455431 - Disclosure - Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails", "shortName": "Stock-Based Compensation Plans (Schedule of Stock Option Activity, Additional Disclosures) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i6448b673e4224460aa2272084f9735a1_I20181231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456432 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)", "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i8744fac63fb74170a2b8308144b9386d_I20171231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458433 - Disclosure - Employee Benefit Plans (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails", "shortName": "Employee Benefit Plans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461434 - Disclosure - Leases (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462435 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails", "shortName": "Leases (Schedule of Rent Expense and Sublease Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.cumberlandpharma.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463436 - Disclosure - Leases (Lease Position) (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails", "shortName": "Leases (Lease Position) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "lang": null, "name": "cpix:LeaseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464437 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails", "shortName": "Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467438 - Disclosure - Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails", "shortName": "Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "ia654c654147f4236bfd24df1f9f50c51_I20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "idd8e653b58b44511801c7359fc7aa9a3_D20190101-20191231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470439 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails", "shortName": "Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "idd8e653b58b44511801c7359fc7aa9a3_D20190101-20191231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "id76d085d544e4897a24652f4073fb63d_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472440 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails", "shortName": "Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "id76d085d544e4897a24652f4073fb63d_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475441 - Disclosure - Discontinued Operations and Disposal Groups (Details)", "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "shortName": "Discontinued Operations and Disposal Groups (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i70c299b338834dbfa0bca910c3806c92_D20191001-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479442 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)", "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails", "shortName": "Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i70c299b338834dbfa0bca910c3806c92_D20191001-20191231", "decimals": "0", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i82b7f6c169a944afb3a13ee3bb463c32_D20170101-20171231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2480443 - Disclosure - Valuation and Qualifying Accounts (Details)", "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails", "shortName": "Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i82b7f6c169a944afb3a13ee3bb463c32_D20170101-20171231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Significant Accounting Policies", "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20191231.htm", "contextRef": "i02b452da8ac14ba980440f0afe2a3b92_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 85, "tag": { "cpix_AccountsReceivableAllowancesByComponentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounts Receivable, Allowances by Component [Axis]", "label": "Accounts Receivable, Allowances by Component [Axis]", "terseLabel": "Accounts Receivable, Allowances by Component [Axis]" } } }, "localname": "AccountsReceivableAllowancesByComponentAxis", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_AccountsReceivableAllowancesByComponentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Accounts Receivable, Allowances by Component [Axis]", "label": "Accounts Receivable, Allowances by Component [Domain]", "terseLabel": "Accounts Receivable, Allowances by Component [Domain]" } } }, "localname": "AccountsReceivableAllowancesByComponentDomain", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_AccruedLiabilitiesInventoryPurchases": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Liabilities, Inventory Purchases", "label": "Accrued Liabilities, Inventory Purchases", "terseLabel": "Accrued inventory purchases" } } }, "localname": "AccruedLiabilitiesInventoryPurchases", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cpix_AccruedLiabilitiesStockPayable": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Liabilities, Stock Payable", "label": "Accrued Liabilities, Stock Payable", "terseLabel": "Stock payable" } } }, "localname": "AccruedLiabilitiesStockPayable", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cpix_AccruedPaymentForAssetPurchaseCurrent": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Payment For Asset Purchase, Current", "label": "Accrued Payment For Asset Purchase, Current", "terseLabel": "Accrued payment for asset purchase" } } }, "localname": "AccruedPaymentForAssetPurchaseCurrent", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cpix_AcetadoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acetadote.", "label": "Acetadote [Member]", "terseLabel": "Acetadote" } } }, "localname": "AcetadoteMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_AmendedInternationalAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended International Agreement [Member]", "label": "Amended International Agreement [Member]", "terseLabel": "Amended International Agreement" } } }, "localname": "AmendedInternationalAgreementMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets and Liabilities, Lessee", "label": "Assets and Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of balance sheet classification" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment", "label": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment", "terseLabel": "Adjustment to initial fair value of the contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses", "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses", "terseLabel": "Contingent consideration earned and accrued in operating expenses" } } }, "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory", "terseLabel": "Finished goods inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill", "totalLabel": "Total intangibles and goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory", "terseLabel": "Raw materials" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials", "terseLabel": "Work in process - unlabeled vials" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials", "terseLabel": "Work in process - validation vials" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_CaldolorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Caldolor.", "label": "Caldolor [Member]", "terseLabel": "Caldolor" } } }, "localname": "CaldolorMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_CashPaidDuringYearForAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Paid During Year For [Abstract]", "label": "Cash Paid During Year For [Abstract]", "terseLabel": "Net cash paid (refunded) during the year for:" } } }, "localname": "CashPaidDuringYearForAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "cpix_ChangeInContingentConsiderationHeadingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change in Contingent Consideration", "label": "Change in Contingent Consideration [Heading Roll Forward]", "terseLabel": "Contingent consideration liability" } } }, "localname": "ChangeInContingentConsiderationHeadingRollForward", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "stringItemType" }, "cpix_ChargebacksCashDiscountsAndDamagedGoodsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Chargebacks, Cash Discounts and Damaged Goods [Member]", "label": "Chargebacks, Cash Discounts and Damaged Goods [Member]", "terseLabel": "Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods" } } }, "localname": "ChargebacksCashDiscountsAndDamagedGoodsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]", "label": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]", "terseLabel": "Collaborative Arrangement, Federal Small Business Grant Programs" } } }, "localname": "CollaborativeArrangementFederalSmallBusinessGrantProgramsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CommonStockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock [Abstract]", "label": "Common Stock [Abstract]", "terseLabel": "Common Stock [Abstract]" } } }, "localname": "CommonStockAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_ContributionOfCashAdditionalSharesPurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contribution of Cash, Additional Shares Purchased", "label": "Contribution of Cash, Additional Shares Purchased", "terseLabel": "Contribution of cash" } } }, "localname": "ContributionOfCashAdditionalSharesPurchased", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_CumberlandEmergingTechnologiesIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumberland Emerging Technologies, Inc [Member]", "label": "Cumberland Emerging Technologies, Inc [Member]", "terseLabel": "Cumberland Emerging Technologies, Inc (CET)" } } }, "localname": "CumberlandEmergingTechnologiesIncMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CustomerFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Five", "label": "Customer Five [Member]", "terseLabel": "Customer 4" } } }, "localname": "CustomerFiveMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CustomerOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer One [Member]", "label": "Customer One [Member]", "terseLabel": "Customer 1" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CustomerThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Three [Member]", "label": "Customer Three [Member]", "terseLabel": "Customer 3" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CustomerTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two [Member]", "terseLabel": "Customer 2" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_DeferredAcquisitionLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Acquisition Liability, Current", "label": "Deferred Acquisition Liability, Current", "terseLabel": "Deferred acquisition liability" } } }, "localname": "DeferredAcquisitionLiabilityCurrent", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses", "label": "Deferred Offering Costs Included in Accounts Payable and Other Accrued Expenses", "terseLabel": "Deferred offering costs included in accounts payable and other accrued expenses" } } }, "localname": "DeferredOfferingCostsIncludedinAccountsPayableandOtherAccruedExpenses", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_DeferredTaxAssetsDeferredCharges": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Deferred Charges", "label": "Deferred Tax Assets, Deferred Charges", "terseLabel": "Deferred charges" } } }, "localname": "DeferredTaxAssetsDeferredCharges", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards", "terseLabel": "Net operating loss and tax credits" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Property and Equipment and Intangibles", "label": "Deferred Tax Assets, Property and Equipment and Intangibles", "terseLabel": "Property and equipment and intangibles" } } }, "localname": "DeferredTaxAssetsPropertyAndEquipmentAndIntangibles", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product", "terseLabel": "Reserve for expired product" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Age", "label": "Defined Contribution Plan, Eligibility, Minimum Employee Age", "terseLabel": "Defined contribution plan, eligibiilty, minimum employee age" } } }, "localname": "DefinedContributionPlanEligibilityMinimumEmployeeAge", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility", "label": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility", "terseLabel": "Defined contribution plan, eligibility, minimum employee service time for participation eligibility" } } }, "localname": "DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "durationStringItemType" }, "cpix_DenominatorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Denominator.", "label": "Denominator [Abstract]", "verboseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation, Including Amortization Related to Leasehold Improvements", "label": "Depreciation, Including Amortization Related to Leasehold Improvements", "terseLabel": "Depreciation, including amortization related to leasehold improvements" } } }, "localname": "DepreciationIncludingAmortizationRelatedToLeaseholdImprovements", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DirectorsIncentivePlan2007Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Directors\u2019 Incentive Plan 2007 [Member]", "label": "Directors\u2019 Incentive Plan 2007 [Member]", "terseLabel": "Directors\u2019 Incentive Plan 2007" } } }, "localname": "DirectorsIncentivePlan2007Member", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActof2017Percent": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act of 2017, Percent", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act of 2017, Percent", "terseLabel": "Change in tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActof2017Percent", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "pureItemType" }, "cpix_EmployeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "cpix_EmployeeNonemployeeandFoundationContributionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee, Nonemployee and Foundation Contribution [Member]", "label": "Employee, Nonemployee and Foundation Contribution [Member]", "terseLabel": "Employee, Nonemployee and Foundation Contribution" } } }, "localname": "EmployeeNonemployeeandFoundationContributionMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "cpix_EmploymentAgreementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employment Agreements [Abstract]", "label": "Employment Agreements [Abstract]" } } }, "localname": "EmploymentAgreementsAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "xbrltype": "stringItemType" }, "cpix_EmploymentAgreementsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employment Agreements", "label": "Employment Agreements [Text Block]", "terseLabel": "Employment Agreements" } } }, "localname": "EmploymentAgreementsTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/EmploymentAgreements" ], "xbrltype": "textBlockItemType" }, "cpix_ExpirationTermFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration, Term Four [Member]", "label": "Expiration, Term Four [Member]", "terseLabel": "2031 - 2039" } } }, "localname": "ExpirationTermFourMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "cpix_ExpirationTermOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration, Term One [Member]", "label": "Expiration, Term One [Member]", "terseLabel": "2020" } } }, "localname": "ExpirationTermOneMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "cpix_ExpirationTermThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration, Term Three [Member]", "label": "Expiration, Term Three [Member]", "terseLabel": "2030" } } }, "localname": "ExpirationTermThreeMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "cpix_ExpirationTermTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration, Term Two [Member]", "label": "Expiration, Term Two [Member]", "terseLabel": "2021 - 2029" } } }, "localname": "ExpirationTermTwoMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "cpix_ExpirationTimePeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration Time Period [Axis]", "label": "Expiration Time Period [Axis]", "terseLabel": "Expiration Time Period [Axis]" } } }, "localname": "ExpirationTimePeriodAxis", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "cpix_ExpirationTimePeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Expiration Time Period [Axis]", "label": "Expiration Time Period [Domain]", "terseLabel": "Expiration Time Period [Domain]" } } }, "localname": "ExpirationTimePeriodDomain", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "cpix_FinancialConsiderationPaymentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Consideration, Payment Period", "label": "Financial Consideration, Payment Period", "terseLabel": "Financial consideration, payment period" } } }, "localname": "FinancialConsiderationPaymentPeriod", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "xbrltype": "durationItemType" }, "cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After", "terseLabel": "2024 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finite-Lived Intangible Assets, Useful Lives, (Textual)", "label": "Finite-Lived Intangible Assets, Useful Lives, (Textual)", "terseLabel": "Intangible assets, useful life" } } }, "localname": "FiniteLivedIntangibleAssetsUsefulLivesTextual", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "cpix_FoundationContributionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foundation Contribution [Member]", "label": "Foundation Contribution [Member]", "terseLabel": "Foundation Contribution" } } }, "localname": "FoundationContributionMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "cpix_GloriaPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gloria Pharmaceuticals", "label": "Gloria Pharmaceuticals [Member]", "terseLabel": "Gloria Pharmaceuticals" } } }, "localname": "GloriaPharmaceuticalsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_HarbinGloriaPharmaceuticalsCoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Harbin Gloria Pharmaceuticals Co [Member]", "label": "Harbin Gloria Pharmaceuticals Co [Member]", "terseLabel": "Harbin Gloria Pharmaceuticals Co" } } }, "localname": "HarbinGloriaPharmaceuticalsCoMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.", "label": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]", "terseLabel": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd." } } }, "localname": "HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "HongKong WinHealth Pharma Group Co. Limited", "label": "HongKong WinHealth Pharma Group Co. Limited [Member]", "terseLabel": "HongKong WinHealth Pharma Group Co. Limited" } } }, "localname": "HongKongWinHealthPharmaGroupCoLimitedMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_IfetrobanClinicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ifetroban Clinical", "label": "Ifetroban Clinical [Member]", "terseLabel": "Ifetroban Clinical" } } }, "localname": "IfetrobanClinicalMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_IndefiniteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indefinite", "label": "Indefinite [Member]", "terseLabel": "Indefinite Period" } } }, "localname": "IndefiniteMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "cpix_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Initial Public Offering [Abstract]", "label": "Initial Public Offering [Abstract]", "terseLabel": "Initial Public Offering [Abstract]" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_IntercompanyLoansPayableConvertedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intercompany Loans Payable, Converted Amount", "label": "Intercompany Loans Payable, Converted Amount", "terseLabel": "Conversion of intercompany loans payable" } } }, "localname": "IntercompanyLoansPayableConvertedAmount", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_KristaloseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kristalose.", "label": "Kristalose [Member]", "terseLabel": "Kristalose" } } }, "localname": "KristaloseMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_LeaseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lease, Asset", "label": "Lease, Asset", "terseLabel": "Total" } } }, "localname": "LeaseAsset", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "cpix_LeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "terseLabel": "Total" } } }, "localname": "LeaseLiability", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions", "label": "Line of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction of Certain Conditions", "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "cpix_LoanPoolsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loan pools.", "label": "Loan Pools [Member]", "verboseLabel": "SBA loan pools - variable rate" } } }, "localname": "LoanPoolsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_LoansForgiveninExchangeForShareIssuedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Loans Forgiven in Exchange For Share Issued, Amount", "label": "Loans Forgiven in Exchange For Share Issued, Amount", "terseLabel": "Loans Forgiven in Exchange For Share Issued, Amount" } } }, "localname": "LoansForgiveninExchangeForShareIssuedAmount", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_LongTermIncentiveCompensationPlan2007Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-Term Incentive Compensation Plan 2007 [Member]", "label": "Long-Term Incentive Compensation Plan 2007 [Member]", "terseLabel": "Long-Term Incentive Compensation Plan 2007" } } }, "localname": "LongTermIncentiveCompensationPlan2007Member", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing agreements, number of primary suppliers for each product", "label": "Manufacturing agreements, number of primary suppliers for each product", "terseLabel": "Manufacturing agreements, number of primary suppliers for each product" } } }, "localname": "ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "cpix_ManufacturingAndSupplyAgreementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing and Supply Agreements [Abstract]", "label": "Manufacturing and Supply Agreements [Abstract]" } } }, "localname": "ManufacturingAndSupplyAgreementsAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "xbrltype": "stringItemType" }, "cpix_ManufacturingAndSupplyAgreementsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing and Supply Agreements", "label": "Manufacturing and Supply Agreements [Text Block]", "terseLabel": "Manufacturing and Supply Agreements" } } }, "localname": "ManufacturingAndSupplyAgreementsTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" ], "xbrltype": "textBlockItemType" }, "cpix_ManufacturingandSupplyAgreementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Manufacturing and Supply Agreement [Table]", "label": "Manufacturing and Supply Agreement [Line Items]", "terseLabel": "Manufacturing and Supply Agreement [Line Items]" } } }, "localname": "ManufacturingandSupplyAgreementLineItems", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_ManufacturingandSupplyAgreementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing and Supply Agreement [Table]", "label": "Manufacturing and Supply Agreement [Table]", "terseLabel": "Manufacturing and Supply Agreement [Table]" } } }, "localname": "ManufacturingandSupplyAgreementTable", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_MethotrexateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Methotrexate [Member]", "label": "Methotrexate [Member]", "terseLabel": "Methotrexate" } } }, "localname": "MethotrexateMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_NetDeferredTaxAssetsGross": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net Deferred Tax Assets, Gross", "label": "Net Deferred Tax Assets, Gross", "totalLabel": "Net deferred tax assets, before valuation allowance" } } }, "localname": "NetDeferredTaxAssetsGross", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "cpix_NoncashOrPartNoncashTransactionVestingOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncash or Part Noncash Transaction, Vesting of Shares", "label": "Noncash or Part Noncash Transaction, Vesting of Shares", "terseLabel": "Vesting of shares related to RediTrex approval" } } }, "localname": "NoncashOrPartNoncashTransactionVestingOfShares", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_NonemployeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nonemployee [Member]", "label": "Nonemployee [Member]", "terseLabel": "Nonemployee" } } }, "localname": "NonemployeeMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "cpix_NonprincipalOwnerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NonPrincipal Owner [Member]", "label": "NonPrincipal Owner [Member]", "terseLabel": "NonPrincipal Owner" } } }, "localname": "NonprincipalOwnerMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_NordicMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nordic", "label": "Nordic [Member]", "terseLabel": "Nordic" } } }, "localname": "NordicMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_NumeratorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Numerator.", "label": "Numerator [Abstract]", "verboseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cpix_OmeclamoxPakMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Omeclamox-Pak [Member]", "label": "Omeclamox-Pak [Member]", "terseLabel": "Omeclamox-Pak", "verboseLabel": "Omeclamox-Pak" } } }, "localname": "OmeclamoxPakMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_OtherRevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenues [Abstract]", "label": "Other Revenues [Abstract]", "terseLabel": "Other Revenues" } } }, "localname": "OtherRevenuesAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_PaymentsForAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments for Asset Acquisitions", "label": "Payments for Asset Acquisitions", "terseLabel": "Payments for asset acquisitions" } } }, "localname": "PaymentsForAssetAcquisitions", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_PaymentsForContingentConsideration": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments for Contingent Consideration", "label": "Payments for Contingent Consideration", "terseLabel": "Fair value of contingent consideration - net sales royalty" } } }, "localname": "PaymentsForContingentConsideration", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_PernixTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pernix Therapeutics [Member]", "label": "Pernix Therapeutics [Member]", "terseLabel": "Pernix Therapeutics" } } }, "localname": "PernixTherapeuticsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_PinnacleBankMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pinnacle Bank [Member]", "label": "Pinnacle Bank [Member]", "terseLabel": "Pinnacle Bank" } } }, "localname": "PinnacleBankMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "cpix_PreferredStockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred Stock [Abstract]", "label": "Preferred Stock [Abstract]", "terseLabel": "Preferred Stock [Abstract]" } } }, "localname": "PreferredStockAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepaids and Other Current Assets, Policy [Policy Text Block]", "label": "Prepaids and Other Current Assets, Policy [Policy Text Block]", "terseLabel": "Prepaid and Other Current Assets" } } }, "localname": "PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cpix_ProductAndLicenseRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product and License Rights [Member]", "label": "Product and License Rights [Member]", "terseLabel": "Product and License Rights" } } }, "localname": "ProductAndLicenseRightsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cpix_ProductEthyolMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product, Ethyol [Member]", "label": "Product, Ethyol [Member]", "terseLabel": "Ethyol" } } }, "localname": "ProductEthyolMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_ProductRevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Revenues [Abstract]", "label": "Product Revenues [Abstract]", "terseLabel": "Product Revenues" } } }, "localname": "ProductRevenuesAbstract", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_ProductRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Rights [Member]", "label": "Product Rights [Member]", "verboseLabel": "Product Rights" } } }, "localname": "ProductRightsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "cpix_ProductSalesRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Product Sales-Related Liabilities, Current", "label": "Product Sales-Related Liabilities, Current", "terseLabel": "Rebates, product returns, administrative fees and service fees" } } }, "localname": "ProductSalesRelatedLiabilitiesCurrent", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cpix_ProductTotectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product, Totect [Member]", "label": "Product, Totect [Member]", "terseLabel": "Totect" } } }, "localname": "ProductTotectMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_ProductVibativMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product, Vibativ", "label": "Product, Vibativ [Member]", "terseLabel": "Vibativ" } } }, "localname": "ProductVibativMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_PropertyAndEquipmentUsefulLifeTextual": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Property and Equipment, useful life (Textual)", "label": "Property and Equipment, useful life (Textual)", "terseLabel": "Property and equipment, useful life (Textual)" } } }, "localname": "PropertyAndEquipmentUsefulLifeTextual", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Purchases of Intangible Assets Incurred But Not Yet Paid", "label": "Purchases of Intangible Assets Incurred But Not Yet Paid", "terseLabel": "Change in unpaid invoices for purchases of intangibles" } } }, "localname": "PurchasesOfIntangibleAssetsIncurredButNotYetPaid", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_RevenueRecognitionCumulativeUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Cumulative Upfront Payment", "label": "Revenue Recognition, Cumulative Upfront Payment", "terseLabel": "Cumulative upfront payment" } } }, "localname": "RevenueRecognitionCumulativeUpfrontPayment", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_RevenueRecognitionMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Milestone Payments", "label": "Revenue Recognition, Milestone Payments", "terseLabel": "Milestone payments associated with international agreements" } } }, "localname": "RevenueRecognitionMilestonePayments", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Potential Upfront Payment Related to Product Sales", "label": "Revenue Recognition, Potential Upfront Payment Related to Product Sales", "terseLabel": "Other revenue, potential upfront payment related to product sales" } } }, "localname": "RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval", "label": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval", "terseLabel": "Other revenue, potential upfront payments related to regulatory approval" } } }, "localname": "RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_RevenueRecognitionUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Upfront Payment", "label": "Revenue Recognition, Upfront Payment", "terseLabel": "Other revenue, upfront payment" } } }, "localname": "RevenueRecognitionUpfrontPayment", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_SalesRevenueGoodsGrossMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales Revenue, Goods, Gross [Member] [Member]", "label": "Sales Revenue, Goods, Gross [Member]", "terseLabel": "Sales Revenue, Goods, Gross" } } }, "localname": "SalesRevenueGoodsGrossMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]", "label": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]", "terseLabel": "Schedule of intangible assets, useful lives" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "cpix_ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]", "label": "Schedule of Stock Option Activity, Additional Disclosures [Table Text Block]", "terseLabel": "Schedule of stock options activity, additional disclosures" } } }, "localname": "ScheduleOfStockOptionActivityAdditionalDisclosuresTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "cpix_ScheduleofDepreciationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Depreciation Expense [Table Text Block]", "label": "Schedule of Depreciation Expense [Table Text Block]", "terseLabel": "Schedule of depreciation expense" } } }, "localname": "ScheduleofDepreciationExpenseTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]", "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]", "terseLabel": "Schedule of rent expense and sublease income" } } }, "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cpix_SecondAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second Amendment", "label": "Second Amendment [Member]", "terseLabel": "Second Amendment" } } }, "localname": "SecondAmendmentMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans", "terseLabel": "Number of equity compensation plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "integerItemType" }, "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants", "terseLabel": "Number of equity compensation plans available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "integerItemType" }, "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value", "terseLabel": "Stock options, exercise price as percent of weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding", "terseLabel": "Exercise of options and related tax benefit, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" ], "xbrltype": "perShareItemType" }, "cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions", "label": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions", "terseLabel": "Committed cash contributions" } } }, "localname": "ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_ShareRepurchaseProgramAuthorizedIn2010Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Repurchase Program Authorized in 2010 [Member]", "label": "Share Repurchase Program Authorized in 2010 [Member]", "terseLabel": "Share Repurchase Program Authorized in 2010" } } }, "localname": "ShareRepurchaseProgramAuthorizedIn2010Member", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_SharebasedCompensationCharitableContributionofSharesShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Charitable Contribution of Shares, Shares", "label": "Share-based Compensation, Charitable Contribution of Shares, Shares", "terseLabel": "Charitable contribution of shares, shares" } } }, "localname": "SharebasedCompensationCharitableContributionofSharesShares", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cpix_SharebasedCompensationFoundationContribution": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Foundation Contribution", "label": "Share-based Compensation, Foundation Contribution", "terseLabel": "Share-based compensation (foundation contribution)" } } }, "localname": "SharebasedCompensationFoundationContribution", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_SharesRepurchaseActivityTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Repurchase Activity, Type [Axis]", "label": "Shares Repurchase Activity, Type [Axis]", "terseLabel": "Shares Repurchase Activity, Type [Axis]" } } }, "localname": "SharesRepurchaseActivityTypeAxis", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cpix_SharesRepurchaseActivityTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Shares Repurchase Activity, Type [Axis]", "label": "Shares Repurchase Activity, Type [Domain]", "terseLabel": "Shares Repurchase Activity, Type [Domain]" } } }, "localname": "SharesRepurchaseActivityTypeDomain", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]", "label": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]", "terseLabel": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options" } } }, "localname": "SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Gross Proceeds from Initial Public Offering", "label": "Stock Issued During Period, Gross Proceeds from Initial Public Offering", "terseLabel": "Initial public offering, gross proceeds" } } }, "localname": "StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, New Shares, Underwriting Discounts", "label": "Stock Issued During Period, New Shares, Underwriting Discounts", "terseLabel": "Initial public offering, underwriting discounts" } } }, "localname": "StockIssuedDuringPeriodNewSharesUnderwritingDiscounts", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_StockIssuedDuringPeriodPricePerShareNewIssues": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Price Per Share, New Issues", "label": "Stock Issued During Period, Price Per Share, New Issues", "terseLabel": "Initial public offering, price per share" } } }, "localname": "StockIssuedDuringPeriodPricePerShareNewIssues", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "perShareItemType" }, "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities", "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities", "terseLabel": "Shelf Registration, sale of corporate securities (up to)" } } }, "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering", "label": "Stock Issued in Initial Public Offering, Number of Shares Common Stock Received for Preferred Stock Contemporareous With Offering", "terseLabel": "Initial public offering, number of shares common stock received in exchange for preferred stock" } } }, "localname": "StockIssuedInInitialPublicOfferingNumberOfSharesCommonStockReceivedForPreferredStockContemporareousWithOffering", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "decimalItemType" }, "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Subsidiary Investment, Payments For Return Of Capital", "label": "Subsidiary Investment, Payments For Return Of Capital", "terseLabel": "Exchange for consideration, amount" } } }, "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_SubsidiaryInvestmentPurchaseOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Subsidiary Investment, Purchase Of Shares", "label": "Subsidiary Investment, Purchase Of Shares", "terseLabel": "Investment in CET" } } }, "localname": "SubsidiaryInvestmentPurchaseOfShares", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Income Tax Expense (Benefit)", "negatedLabel": "Net tax benefit" } } }, "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense (Benefit)", "terseLabel": "Revaluation of deferred income tax balances for new rates under TCJA" } } }, "localname": "TaxCutsandJobsActof2017ChangeinTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "cpix_TieredRoyaltyPaymentsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tiered Royalty Payments, Percentage", "label": "Tiered Royalty Payments, Percentage", "terseLabel": "Tiered royalty payments (percentage)" } } }, "localname": "TieredRoyaltyPaymentsPercentage", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails" ], "xbrltype": "percentItemType" }, "cpix_USTreasuryNotesAndBondsSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "US Treasury Notes And Bonds Securities", "label": "US Treasury Notes And Bonds Securities [Member]", "terseLabel": "U.S. Treasury notes and bonds" } } }, "localname": "USTreasuryNotesAndBondsSecuritiesMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_VIBATIVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VIBATIV", "label": "VIBATIV [Member]", "terseLabel": "VIBATIV" } } }, "localname": "VIBATIVMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "domainItemType" }, "cpix_VaprisolMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vaprisol [Member]", "label": "Vaprisol [Member]", "verboseLabel": "Vaprisol" } } }, "localname": "VaprisolMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "cpix_WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants, Issued in Consideration of 2006 Credit Facility Amendment [Member]", "label": "Warrants, Issued in Consideration of 2006 Credit Facility Amendment [Member]", "terseLabel": "Warrants, Issued in Consideration of 2006 Credit Facility Amendment" } } }, "localname": "WarrantsIssuedInConsiderationOf2006CreditFacilityAmendmentMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]", "label": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment [Member]", "terseLabel": "Warrants, Issued in Consideration of 2009 Credit Facility Amendment" } } }, "localname": "WarrantsIssuedInConsiderationOf2009CreditFacilityAmendmentMember", "nsuri": "http://www.cumberlandpharma.com/20191231", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r404" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r400" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r56", "r103", "r408" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r156", "r220", "r224" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Major Customers [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails", "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails", "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Name of Major Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r154", "r220", "r222", "r392" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails", "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails", "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r114", "r407" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "verboseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r155", "r220", "r223", "r394", "r396", "r405", "r406" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "verboseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2018-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r114", "r407" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r19", "r221" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts receivable, net of allowances" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r187" ], "calculation": { "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Revenues" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r99", "r171", "r172" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.", "label": "Advertising Costs, Policy [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AirlineProductsAndServicesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.", "label": "Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "AirlineProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r51", "r160" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Accounts receivable, allowances, current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r66", "r89", "r350" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Noncash interest expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r89", "r176", "r181" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]", "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r151", "r370", "r383" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r55" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r233", "r258" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r305", "r306", "r309" ], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r303", "r305", "r306", "r311" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Liabilities incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "auth_ref": [ "r88", "r313" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "negatedLabel": "Decrease in non-cash contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r88", "r313" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration included in operating expenses" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r304", "r307", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at December 31, 2018", "periodStartLabel": "Balance at November 12, 2018", "terseLabel": "Liability to be paid" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r304", "r308" ], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of accrued contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r304", "r308" ], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Noncurrent portion of accrued contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Omeclamox\u00ae-Pak, RediTrex\u00ae and Vibativ\u00ae" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativ" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r298" ], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r297", "r298" ], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 1.0, "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intellectual property amortizable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r297", "r298" ], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "totalLabel": "Total inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r32", "r91" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r92", "r99", "r157" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r91", "r97" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r348" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r210", "r211", "r212", "r213" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r111", "r214", "r215", "r230" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants, exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants, number of shares called by warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r102", "r214", "r215", "r230" ], "lang": { "en-US": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r98", "r315" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaborative Agreements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r192", "r376", "r389" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r191", "r193" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "verboseLabel": "Common stock, no par value (dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, number of shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, number of shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r201" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Equity, common shares outstanding", "periodStartLabel": "Equity, common shares outstanding", "verboseLabel": "Common stock, number of shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r18" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "verboseLabel": "Common stock \u2013 no par value; 100,000,000 shares authorized; 15,263,555 and 15,481,497 shares issued and outstanding as of December\u00a031, 2019 and 2018, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r59", "r61", "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r61", "r319", "r331" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income (loss) attributable to common shareholders" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r138", "r139", "r345", "r346" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r138", "r139", "r345", "r346", "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r138", "r139", "r345", "r346", "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Market Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r138", "r139", "r345", "r346" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r136", "r138", "r139", "r140", "r345", "r347" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r138", "r139", "r345", "r346" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.", "label": "Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset", "terseLabel": "Financial consideration" } } }, "localname": "ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r99", "r323", "r332", "r333" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r69" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r67" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect from change in accounting principle (Note 12)" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r101", "r284", "r291" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "negatedTerseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r284", "r291" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "negatedTotalLabel": "Total current income tax (expense) benefit" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r101", "r284", "r291" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "negatedTerseLabel": "State and other" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r371", "r372", "r382" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Compensation Liability [Abstract]", "terseLabel": "Deferred Compensation Arrangements [Abstract]" } } }, "localname": "DeferredCompensationLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current and Noncurrent", "terseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r285", "r291" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r101", "r285", "r291" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredOtherTaxExpenseBenefit": { "auth_ref": [ "r108", "r286", "r287", "r290" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.", "label": "Deferred Other Tax Expense (Benefit)", "negatedTotalLabel": "Deferred income tax (expense) benefit" } } }, "localname": "DeferredOtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r285", "r291" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "negatedTerseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r276" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 1.0, "parentTag": "cpix_NetDeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r266", "r282", "r283" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r278" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r269", "r270", "r278" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r265", "r282", "r283" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Cumulative compensation costs incurred on deductible equity awards" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r265", "r282", "r283" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts", "terseLabel": "Allowance for accounts receivable" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r277" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Less: deferred tax asset valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred Tax Liabilities" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r266", "r282", "r283" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": { "order": 2.0, "parentTag": "cpix_NetDeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedTerseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Contribution Plan [Abstract]", "terseLabel": "Defined Contribution Plan [Abstract]" } } }, "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Defined contribution plan, employer discretionary contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r89", "r149" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r216", "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r0", "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DiscontinuedOperationsandDisposalGroups" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share attributable to common shareholders", "verboseLabel": "Earnings (loss) per share attributable to common shareholders:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r65", "r116", "r119", "r121", "r122", "r123", "r127", "r379", "r391" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r65", "r116", "r119", "r121", "r122", "r123", "r127", "r379", "r391" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r99", "r124", "r125", "r126" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (loss) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r107", "r271", "r272" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Net income tax expense" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r271", "r272", "r289" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal tax expense at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r271", "r272", "r289" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r271", "r272", "r289" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Other permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r271", "r272", "r289" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r271", "r272", "r289" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income tax expense (net of federal income tax benefit)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r271", "r272", "r289" ], "calculation": { "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Permanent differences associated with general business credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee wages and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Unrecognized compensation cost related to share-based payments" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost related to share-based payments, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r261" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedLabel": "Excess tax (benefit) expense derived from exercise of stock options" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r335", "r336", "r337", "r338", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r335", "r336", "r337", "r338", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of fair value of financial instruments by level in hierarchy" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r339", "r341" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Fair Value by Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r336", "r341" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r226", "r227", "r228", "r337", "r366" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r226", "r227", "r228", "r337", "r367" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r226", "r227", "r228", "r337", "r368" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r99", "r342", "r344" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r180" ], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r182" ], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r182" ], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r182" ], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r182" ], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r177", "r178", "r180", "r183", "r369" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r180", "r369" ], "calculation": { "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r177", "r179" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r180" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r173", "r174" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 2.0, "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Increase in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r99", "r185", "r189" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r150", "r292" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit", "negatedTotalLabel": "Total income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r99", "r267", "r268", "r274", "r275", "r279", "r293", "r395" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r88" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Net changes in assets and liabilities affecting operating activities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r88" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Prepaid, other current assets and other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r120", "r125" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of restricted stock and stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r99", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r63", "r148", "r349", "r350", "r380" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r82", "r85", "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r25", "r169" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods", "verboseLabel": "Finished goods, net of reserve" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r52" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total inventories" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r52", "r165" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "negatedLabel": "less non-current inventories", "terseLabel": "Non-current inventories" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r53", "r99", "r129", "r166", "r167" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r26", "r169" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials and work in process" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r52", "r114", "r165", "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory reserves, obsolescence and discontinuance" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r71", "r147" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r355", "r363" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of operating lease liability maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "After 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r361" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r374", "r386" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Rights" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r38", "r105" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r38", "r105" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit, unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r45", "r195", "r196" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "verboseLabel": "Revolving line of credit" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturedProductOtherMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by labor or machinery, classified as other.", "label": "Manufactured Product, Other [Member]", "terseLabel": "Other" } } }, "localname": "ManufacturedProductOtherMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r4", "r40" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r50", "r373", "r385" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r208", "r321", "r322" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Repurchase of subsidiary shares to noncontrolling interest", "negatedTerseLabel": "Repurchase of subsidiary shares from noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "verboseLabel": "Short-term cash investments" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r87", "r90" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r57", "r60", "r64", "r90", "r125", "r378", "r390" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss) attributable to common shareholders", "verboseLabel": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails", "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r57", "r60", "r325", "r330" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests", "negatedTerseLabel": "Net loss at subsidiary allocated to noncontrolling interests", "terseLabel": "Net loss at subsidiary attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Guidance" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Additions to intangible assets from final purchase price allocation" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.", "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed", "terseLabel": "Non cash increase in liabilities related to acquisition (see Note 3)" } } }, "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": { "auth_ref": [ "r209", "r321", "r327" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.", "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest", "terseLabel": "Exercise of options and related tax benefit" } } }, "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r209", "r321", "r327" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Sale of subsidiary shares to noncontrolling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "verboseLabel": "Noncontrolling interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income (loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r357" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails", "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r357" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease current liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r357" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r356" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails", "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r360", "r362" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r359", "r362" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "terseLabel": "Future minimum sublease income under noncancelable operating subleases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r351", "r352" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "After 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.", "label": "Operating Leases, Rent Expense, Sublease Rentals", "terseLabel": "Sublease income" } } }, "localname": "OperatingLeasesRentExpenseSubleaseRentals1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r334" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r58", "r61", "r319", "r320", "r328" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net loss at subsidiary attributable to noncontrolling interests" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": { "auth_ref": [ "r52" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.", "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross", "terseLabel": "Consigned inventory" } } }, "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r41" ], "calculation": { "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Current [Abstract]" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Current and Other Long-term Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "totalLabel": "Other Liabilities, Noncurrent, Total", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingGainsLosses": { "auth_ref": [ "r72" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Gains (Losses)", "negatedTerseLabel": "Noncash investment gains" } } }, "localname": "OtherNonoperatingGainsLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPaymentsToAcquireBusinesses": { "auth_ref": [ "r74" ], "calculation": { "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.", "label": "Other Payments to Acquire Businesses", "terseLabel": "Cash payment during early 2019", "verboseLabel": "Additional payments to acquire businesses" } } }, "localname": "OtherPaymentsToAcquireBusinesses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Cash payments of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r78" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "terseLabel": "Cash payment of royalty during the period" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r81" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payments of financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r81" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payments of deferred equity offering costs", "terseLabel": "Initial public offering, issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r74", "r310" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 }, "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedLabel": "Cash paid for acquisition", "terseLabel": "Cash paid at closing", "verboseLabel": "Payments to acquire businesses" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Additions to intangible assets", "terseLabel": "Additions to intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "terseLabel": "Payments to acquire interest in subsidiaries" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r164" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r75" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r233", "r258" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r30", "r31" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrincipalOwnerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.", "label": "Principal Owner [Member]", "terseLabel": "Principal Owner" } } }, "localname": "PrincipalOwnerMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Initial public offering, net proceeds" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r77" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Sale of subsidiary shares to noncontrolling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r112" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "verboseLabel": "Borrowings on line of credit" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r73" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-term Investments", "terseLabel": "Proceeds from sale of marketable securities" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r76", "r259" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Sales of shares of common stock, net of offering costs" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProductionAndDistributionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to the production and distribution of goods or services to customers and clients.", "label": "Production and Distribution Costs", "terseLabel": "Distribution costs" } } }, "localname": "ProductionAndDistributionCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r57", "r60", "r83", "r151", "r153", "r319", "r324", "r326", "r330", "r331" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r186" ], "calculation": { "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r188", "r388" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r99", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r188" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r186" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Information (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r79" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Repayments on line of credit" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r264", "r397" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r99", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r208", "r384" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r218", "r219", "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r100", "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r68", "r145", "r146", "r152" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net revenues from customers outside the United States", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r358", "r362" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockTransactionDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date the subsidiary or equity investee issued or sold stock, in CCYY-MM-DD format.", "label": "Sale of Stock, Transaction Date", "terseLabel": "Initial public offering, effective date" } } }, "localname": "SaleOfStockTransactionDate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of anti-dilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of the components of income tax benefit (expense)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities, net" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of calculation of numerator and denominator in earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r231", "r256", "r260" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "verboseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of net product revenues by product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r177", "r179" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r177", "r179" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of future minimum lease payments for operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r27", "r28", "r29" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories, current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r35", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of quarterly financial information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r233", "r258" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r240", "r251", "r254" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r48", "r104", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected amortization expense of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r136", "r138", "r139", "r140", "r345", "r347" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of revenues concentration from major customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "verboseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Shares forfeited, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Shares forfeited, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Shares granted, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, end of period, shares", "periodStartLabel": "Nonvested, beginning of period, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, end of period, weighted-average grant-date fair value", "periodStartLabel": "Nonvested, beginning of period, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted- average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Shares vested, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Shares vested, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares reserved for issuance under equity compensation plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Options, exerciseable, end of period, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable, end of period, weighted-average exercise price per share (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r253" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options forfeited or expired, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited or expired, weighted-average exercise price per share (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding, end of period, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r242", "r258" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period, shares", "periodStartLabel": "Outstanding, beginning of period, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in USD per share)", "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-average exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r230", "r237" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised, weighted-average exercise price per share (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted, weighted-average exercise price per share (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r99", "r233", "r238" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-Based Payments" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Stock options, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, end of period, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, end of period, weighted-average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Vesting of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vesting of common stock, shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r201" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r49", "r201" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r17", "r18", "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Stock issued during period, acquisitions (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r201", "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Initial public offering, shares issued", "verboseLabel": "Proceeds from the sale of common stock, net of offering costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r17", "r18", "r201", "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r201", "r208", "r244" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r49", "r201", "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Stock issued during period, acquisitions" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r201", "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from sale of common stock, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r17", "r18", "r208", "r232", "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based compensation, amount", "verboseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r49", "r201", "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of options and related tax benefit" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program, number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Amount available under current repurchase program" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r17", "r18", "r201", "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of common shares, shares", "terseLabel": "Repurchase of common shares, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r17", "r18", "r201", "r208" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of common shares", "terseLabel": "Repurchase of common shares, value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r162" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r317", "r318", "r329" ], "calculation": { "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, balance", "periodStartLabel": "Equity, balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativVibativAcquisitionNarrativeDetails", "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Summary of Operating Loss Carryforwards [Table Text Block]", "terseLabel": "Schedule of federal and state net operating loss carryforwards" } } }, "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Title of Individual with Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails", "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r19", "r24", "r99", "r158", "r159", "r161", "r163", "r375", "r387" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.", "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Fair value of marketable securities" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]", "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OmeclamoxPakRediTrexandVibativNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r132", "r133", "r134", "r135", "r141", "r142", "r143" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Valuation allowance for deferred tax assets:" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charged to costs and expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "terseLabel": "Charged to other accounts" } } }, "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)", "terseLabel": "Increase in valuation allowance during the year" } } }, "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails", "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r123" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r117", "r123" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=84159346&loc=d3e8275-108329" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68054294&loc=d3e8384-108330" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11374-113907" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r398": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r399": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r401": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r402": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r403": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r404": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r405": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r406": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r407": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r408": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7,9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" } }, "version": "2.1" }